首页 > 最新文献

Current drug safety最新文献

英文 中文
Hepatitis E Virus in Individuals Undergoing Heparin Therapy: An Observational Serological and Molecular Study. 接受治疗者中的戊型肝炎病毒:一项观察性血清学和分子研究。
IF 1.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/0115748863272272231122114732
João R Mesquita, Sérgio Santos-Silva, Nanci Ferreira, Antonio Rivero-Juarez, Guilherme Gonçalves, Maria São José Nascimento

Introduction: Heparin is derived from swine and has been suggested as a possible source of HEV. To study the potential risk of HEV infection associated with heparin treatment, two groups of individuals were compared. Sera from heparinized (N=93) and non-heparinized individuals (N=111) were tested for markers of acute HEV infection and anti-HEV IgG seroprevalence.

Methods: An acute HEV case was defined by the presence of anti-HEV IgM and/or HEV RNA. From the 93 heparinized individuals, one was positive for IgM and IgG anti-HEV and two were positive for HEV RNA (for both ORF3 and ORF2), and there were a total of two (2.2%) cases of current or recent HEV infection. From the 111 non-heparinized individuals, three were positive for IgM anti-HEV, one was positive for both IgM and IgG anti-HEV, and none was positive for HEV RNA, and there were a total of three (2.7%) cases of current or recent HEV infection. The difference between HEV cases in the heparinized individuals and the non-heparinized individuals was not statistically significant (2.2% vs. 2.7%; p = 0.799).

Results: Concerning IgG anti-HEV, it was detected in 32 individuals from the heparinized group and in 18 from the non-heparinized control group. A statistically significant difference was observed in the presence of anti-HEV IgG in heparinized individuals and controls (p = 0.003).

Conclusion: This study has not found any association between heparin treatment and acute HEV infection, but has shown the use of therapeutic heparin as a risk factor for IgG anti-HEV seropositivity.

简介:肝素来自猪,被认为可能是 HEV 的来源。为了研究与肝素治疗相关的 HEV 感染潜在风险,我们对两组人进行了比较。对肝素治疗者(93 人)和非肝素治疗者(111 人)的血清进行了急性 HEV 感染标记物和抗 HEV IgG 血清流行率检测:急性 HEV 病例的定义是出现抗 HEV IgM 和/或 HEV RNA。在 93 名肝素感染者中,1 人的抗 HEV IgM 和 IgG 阳性,2 人的 HEV RNA 阳性(ORF3 和 ORF2),共有 2 人(2.2%)目前或近期感染 HEV。在 111 名未接受肝素治疗的人中,有 3 人的 IgM 抗 HEV 阳性,1 人的 IgM 和 IgG 抗 HEV 阳性,没有人的 HEV RNA 阳性,共有 3 例(2.7%)目前或近期感染 HEV 的病例。肝素注射者与非肝素注射者的 HEV 感染病例差异无统计学意义(2.2% 对 2.7%;P = 0.799):关于抗 HEV IgG,肝素化疗组的 32 人和非肝素化疗对照组的 18 人中都检测到了抗 HEV IgG。肝素化疗组和非肝素化疗对照组的抗 HEV IgG 存在统计学差异(p = 0.003):本研究未发现肝素治疗与急性 HEV 感染之间存在任何关联,但表明使用治疗性肝素是导致抗 HEV IgG 血清阳性的一个危险因素。
{"title":"Hepatitis E Virus in Individuals Undergoing Heparin Therapy: An Observational Serological and Molecular Study.","authors":"João R Mesquita, Sérgio Santos-Silva, Nanci Ferreira, Antonio Rivero-Juarez, Guilherme Gonçalves, Maria São José Nascimento","doi":"10.2174/0115748863272272231122114732","DOIUrl":"10.2174/0115748863272272231122114732","url":null,"abstract":"<p><strong>Introduction: </strong>Heparin is derived from swine and has been suggested as a possible source of HEV. To study the potential risk of HEV infection associated with heparin treatment, two groups of individuals were compared. Sera from heparinized (N=93) and non-heparinized individuals (N=111) were tested for markers of acute HEV infection and anti-HEV IgG seroprevalence.</p><p><strong>Methods: </strong>An acute HEV case was defined by the presence of anti-HEV IgM and/or HEV RNA. From the 93 heparinized individuals, one was positive for IgM and IgG anti-HEV and two were positive for HEV RNA (for both ORF3 and ORF2), and there were a total of two (2.2%) cases of current or recent HEV infection. From the 111 non-heparinized individuals, three were positive for IgM anti-HEV, one was positive for both IgM and IgG anti-HEV, and none was positive for HEV RNA, and there were a total of three (2.7%) cases of current or recent HEV infection. The difference between HEV cases in the heparinized individuals and the non-heparinized individuals was not statistically significant (2.2% vs. 2.7%; p = 0.799).</p><p><strong>Results: </strong>Concerning IgG anti-HEV, it was detected in 32 individuals from the heparinized group and in 18 from the non-heparinized control group. A statistically significant difference was observed in the presence of anti-HEV IgG in heparinized individuals and controls (p = 0.003).</p><p><strong>Conclusion: </strong>This study has not found any association between heparin treatment and acute HEV infection, but has shown the use of therapeutic heparin as a risk factor for IgG anti-HEV seropositivity.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":"377-381"},"PeriodicalIF":1.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139416593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tumor Necrosis Alpha (TNF-α) Antagonists Used in Chronic Inflammatory Rheumatic Diseases: Risks and their Minimization Measures. 用于慢性炎症性风湿病的肿瘤坏死α(TNF-α)拮抗剂:风险及其最小化措施。
IF 1.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/0115748863274863231222023853
Rim Lakhmiri, Yahia Cherrah, Samira Serragui

Tumor necrosis factor alpha (TNF- α) inhibitors are widely employed for the management of chronic inflammatory rheumatism. However, their usage carries significant risks, including site and infusion reactions, serious infections, malignancy, heart failure autoimmune and demyelinating disorders. These risks are comprehensively outlined in risk management plans (RMPs) associated with these molecules. RMP provides information on the safety profile of a medicinal product as well as the measures that will be taken to minimize risks; these are known as risk minimization measures. These measures are divided into routine measures related to elements, such as the summary of product characteristics, labeling, pack size, package leaflet, or legal supply status of the product, while additional measures may include educational programs, including tools for healthcare providers and patients, controlled access or pregnancy prevention programs, among others. Additional measures can consist of one or more interventions that need to be implemented in a sustainable way in a defined target group, while respecting the timing and frequency of any intervention and procedures to reach the target population. An evaluation of the effectiveness of these measures is required to determine whether or not an intervention has been effective. This comprehensive review offers an in-depth exploration of the current treatment, uses, and associated risks of TNF-α inhibitors. Additionally, it provides a detailed account of risk minimization measures and risk management practices while shedding light on their real-world implementation and effectiveness.

肿瘤坏死因子α(TNF- α)抑制剂被广泛用于治疗慢性炎症性风湿病。然而,使用这些药物也有很大的风险,包括用药部位和输液反应、严重感染、恶性肿瘤、心力衰竭、自身免疫性疾病和脱髓鞘疾病。与这些分子相关的风险管理计划(RMP)全面概述了这些风险。风险管理计划提供了有关医药产品安全概况的信息,以及为将风险降至最低而采取的措施;这些措施被称为风险最小化措施。这些措施分为与产品特征概要、标签、包装尺寸、包装说明书或产品的合法供应状态等要素相关的常规措施,而附加措施可能包括教育计划,包括针对医疗保健提供者和患者的工具、控制使用或怀孕预防计划等。附加措施可包括一项或多项干预措施,需要以可持续的方式在确定的目标群体中实施,同时尊重任何干预措施和程序到达目标人群的时间和频率。需要对这些措施的有效性进行评估,以确定干预措施是否有效。本综述深入探讨了TNF-α抑制剂目前的治疗方法、用途和相关风险。此外,它还详细介绍了风险最小化措施和风险管理实践,同时揭示了这些措施和实践在现实世界中的实施情况和有效性。
{"title":"Tumor Necrosis Alpha (TNF-α) Antagonists Used in Chronic Inflammatory Rheumatic Diseases: Risks and their Minimization Measures.","authors":"Rim Lakhmiri, Yahia Cherrah, Samira Serragui","doi":"10.2174/0115748863274863231222023853","DOIUrl":"10.2174/0115748863274863231222023853","url":null,"abstract":"<p><p>Tumor necrosis factor alpha (TNF- α) inhibitors are widely employed for the management of chronic inflammatory rheumatism. However, their usage carries significant risks, including site and infusion reactions, serious infections, malignancy, heart failure autoimmune and demyelinating disorders. These risks are comprehensively outlined in risk management plans (RMPs) associated with these molecules. RMP provides information on the safety profile of a medicinal product as well as the measures that will be taken to minimize risks; these are known as risk minimization measures. These measures are divided into routine measures related to elements, such as the summary of product characteristics, labeling, pack size, package leaflet, or legal supply status of the product, while additional measures may include educational programs, including tools for healthcare providers and patients, controlled access or pregnancy prevention programs, among others. Additional measures can consist of one or more interventions that need to be implemented in a sustainable way in a defined target group, while respecting the timing and frequency of any intervention and procedures to reach the target population. An evaluation of the effectiveness of these measures is required to determine whether or not an intervention has been effective. This comprehensive review offers an in-depth exploration of the current treatment, uses, and associated risks of TNF-α inhibitors. Additionally, it provides a detailed account of risk minimization measures and risk management practices while shedding light on their real-world implementation and effectiveness.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":"431-443"},"PeriodicalIF":1.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139416596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antidepressant-induced Paradoxical Anxiety, Akathisia, and Complex Vocal Tics in a Patient with Panic Disorder and Crohn's Disease: A Case Report. 一名患有恐慌症和克罗恩病的患者因抗抑郁药诱发的矛盾焦虑、肌痉挛和复杂发声抽搐:病例报告。
IF 1.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/0115748863270093231114075934
Azriel H K Koh, Soon Shan Loh, Leslie Lim

Background: Antidepressant-induced paradoxical anxiety is a fairly common phenomenon seen in patients who are initiated on antidepressants. However, akathisia is a very uncommon manifestation of antidepressants. Much more rarely, antidepressants are also associated with the emergence of motor and vocal tics. This case adds to the growing literature of rare adverse events induced by antidepressants and aims to stimulate future research into the mechanism and risk factors of this phenomenon.

Case presentation: In this case report, we describe a patient with panic disorder and co-morbid Crohn's disease who developed worsening anxiety, akathisia and vocal tics upon initiation of fluvoxamine. This is the first case report to describe the emergence of both akathisia and vocal tics in the same patient following antidepressant initiation. After discontinuation of fluvoxamine, the patient's symptoms resolved.

Conclusion: Antidepressant-induced akathisia and tics are often distressing both to the patient and their loved ones, and can be very puzzling to the clinician. It is important for clinicians to recognise that, although rare, antidepressants can adverse effects. When these symptoms arise, it should prompt immediate discontinuation of the offending antidepressant.

背景:抗抑郁药诱发的反常焦虑是一种在开始服用抗抑郁药的患者中相当常见的现象。然而,无运动症状是抗抑郁药的一种非常罕见的表现。更罕见的是,抗抑郁药还与运动和发声抽搐的出现有关。本病例为越来越多的有关抗抑郁药物诱发罕见不良事件的文献增添了新的内容,旨在促进今后对这一现象的机制和风险因素的研究:在本病例报告中,我们描述了一名患有惊恐障碍并合并克罗恩病的患者在开始服用氟伏沙明后出现焦虑加重、运动障碍和发声抽搐。这是首例描述同一患者在开始服用抗抑郁药后同时出现运动障碍和发声抽搐的病例报告。停用氟伏沙明后,患者的症状得到缓解:结论:抗抑郁药诱发的运动失调和抽搐通常会给患者及其亲人带来痛苦,也会让临床医生感到非常困惑。临床医生必须认识到,抗抑郁药虽然罕见,但也会给患者带来抽动和抽搐的不良反应。一旦出现这些症状,应立即停用违规抗抑郁药。
{"title":"Antidepressant-induced Paradoxical Anxiety, Akathisia, and Complex Vocal Tics in a Patient with Panic Disorder and Crohn's Disease: A Case Report.","authors":"Azriel H K Koh, Soon Shan Loh, Leslie Lim","doi":"10.2174/0115748863270093231114075934","DOIUrl":"10.2174/0115748863270093231114075934","url":null,"abstract":"<p><strong>Background: </strong>Antidepressant-induced paradoxical anxiety is a fairly common phenomenon seen in patients who are initiated on antidepressants. However, akathisia is a very uncommon manifestation of antidepressants. Much more rarely, antidepressants are also associated with the emergence of motor and vocal tics. This case adds to the growing literature of rare adverse events induced by antidepressants and aims to stimulate future research into the mechanism and risk factors of this phenomenon.</p><p><strong>Case presentation: </strong>In this case report, we describe a patient with panic disorder and co-morbid Crohn's disease who developed worsening anxiety, akathisia and vocal tics upon initiation of fluvoxamine. This is the first case report to describe the emergence of both akathisia and vocal tics in the same patient following antidepressant initiation. After discontinuation of fluvoxamine, the patient's symptoms resolved.</p><p><strong>Conclusion: </strong>Antidepressant-induced akathisia and tics are often distressing both to the patient and their loved ones, and can be very puzzling to the clinician. It is important for clinicians to recognise that, although rare, antidepressants can adverse effects. When these symptoms arise, it should prompt immediate discontinuation of the offending antidepressant.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":"478-481"},"PeriodicalIF":1.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139512052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Review of Drug Abuse, Misuse, and Related Laboratory Challenges. 药物滥用、误用和相关实验室挑战综述。
IF 1.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/0115748863266621231023112044
Haniye Ranjkeshzadeh, Samaneh Sepahi, Hadi Zare-Zardini, Mohammad Ehsan Taghavizadeh Yazdi, Adel Ghorani-Azam, Abbas Jafari

Various definitions can be considered for drugs and substance abuse. According to the National Institute on Abuse, the use of an over-the-counter drug in a different way than that prescribed to experience or arouse emotion is a simple form of drug abuse. The World Health Organization (WHO) also defines drug abuse as the persistent or sporadic use of drugs that are incompatible or unrelated to acceptable medical practice. With the increasing non-therapeutic use of prescription drugs, serious related consequences have also increased. Therefore, there is a need to know more precisely about the types of substances and drug abuse, which is the most important part of diagnosis and recognizing the tests that cause false positive and negative results. The purpose of this review article is to collect and summarize the most important and more common types of drugs of abuse and review the drugs that cause false results in screening tests. In addition, the most common detection methods of the drug will be reviewed and the advantages and drawbacks of each method will be discussed. In this article, we aimed to point out all the facts about the emerging problems in drug abuse, the methods of screening, and the possible false results in addition to troubleshooting strategies.

对毒品和药物滥用可以考虑不同的定义。根据国家滥用研究所的说法,以不同于处方的方式使用非处方药来体验或唤起情感是一种简单的药物滥用形式。世界卫生组织(世卫组织)还将药物滥用定义为持续或零星使用与可接受的医疗做法不相容或无关的药物。随着处方药非治疗性使用的增加,严重的相关后果也在增加。因此,有必要更准确地了解物质和药物滥用的类型,这是诊断和识别导致假阳性和阴性结果的测试的最重要部分。这篇综述文章的目的是收集和总结最重要和最常见的药物滥用类型,并回顾在筛选试验中导致错误结果的药物。此外,还将回顾最常用的药物检测方法,并讨论每种方法的优缺点。在这篇文章中,我们的目的是指出所有的事实,在药物滥用的新出现的问题,筛选的方法,以及可能的错误结果,除了排除故障的策略。
{"title":"A Review of Drug Abuse, Misuse, and Related Laboratory Challenges.","authors":"Haniye Ranjkeshzadeh, Samaneh Sepahi, Hadi Zare-Zardini, Mohammad Ehsan Taghavizadeh Yazdi, Adel Ghorani-Azam, Abbas Jafari","doi":"10.2174/0115748863266621231023112044","DOIUrl":"10.2174/0115748863266621231023112044","url":null,"abstract":"<p><p>Various definitions can be considered for drugs and substance abuse. According to the National Institute on Abuse, the use of an over-the-counter drug in a different way than that prescribed to experience or arouse emotion is a simple form of drug abuse. The World Health Organization (WHO) also defines drug abuse as the persistent or sporadic use of drugs that are incompatible or unrelated to acceptable medical practice. With the increasing non-therapeutic use of prescription drugs, serious related consequences have also increased. Therefore, there is a need to know more precisely about the types of substances and drug abuse, which is the most important part of diagnosis and recognizing the tests that cause false positive and negative results. The purpose of this review article is to collect and summarize the most important and more common types of drugs of abuse and review the drugs that cause false results in screening tests. In addition, the most common detection methods of the drug will be reviewed and the advantages and drawbacks of each method will be discussed. In this article, we aimed to point out all the facts about the emerging problems in drug abuse, the methods of screening, and the possible false results in addition to troubleshooting strategies.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":"417-430"},"PeriodicalIF":1.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92153083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Case Report of Cefixime, Paracetamol, and Nimesulide Induced Toxic Epidermal Necrolysis in a Woman with Dengue Infection without any Other Associated Comorbidities. 一名登革热感染妇女因头孢克肟、扑热息痛和尼美舒利诱发中毒性表皮坏死症的病例报告,该妇女无任何其他相关并发症。
IF 1.5 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/1574886318666230418104445
Renuka Munshi, Miteshkumar Maurya

Background: Toxic Epidermal Necrolysis (TEN) is a rare, acute, and life-threatening mucocutaneous disease that occurs after the administration of certain drugs, resulting in extensive keratinocyte cell death, skin involvement at the dermal-epidermal junction, and extensive bullous skin eruptions and sloughing. Many published case reports have observed the presence of fever with a viral infection, drug, and/or genetic association as a possible trigger for TEN but associated with other comorbidities. Physicians still struggle to predict which individuals could be predisposed to TEN. The case report that we present had a history of multiple drug intake and fever due to dengue virus infection but was not associated with any other comorbidity.

Case presentation: We present an unusual case of a 32-year-old woman of Western Indian origin who had developed dengue infection and suffered toxic epidermal necrolysis following a five-day course of a third-generation cephalosporin antibiotic, cefixime and a three-day course of 2 analgesic drugs, paracetamol (acetaminophen), and nimesulide, with the adverse event occurring on the fifth day of the dengue infection. The offending drugs were stopped, and patient survived with supportive management and hydration.

Conclusion: The presence of comorbidities may not always be the triggering factor for TEN, though it can affect patient outcomes. Rational drug use is always recommended for patient care. Further research is required to understand the pathomechanism behind the viral-drug-gene interaction.

背景:中毒性表皮坏死溶解症(TEN)是一种罕见的急性皮肤黏膜疾病,在服用某些药物后发生,可导致大量角质细胞死亡、真皮-表皮交界处皮肤受累、大面积牛皮状皮肤糜烂和脱落,危及生命。许多已发表的病例报告观察到,发热与病毒感染、药物和/或遗传有关,可能是 TEN 的诱发因素,但也与其他合并症有关。医生仍在努力预测哪些人可能易患 TEN。我们报告的病例有多种药物摄入史和登革热病毒感染引起的发热史,但与其他合并症无关:病例介绍:我们报告了一例不寻常的病例,一名 32 岁的西印度裔女性在感染登革热后出现中毒性表皮坏死,当时她服用了第三代头孢菌素抗生素头孢克肟 5 天疗程,以及 2 种镇痛药物扑热息痛(对乙酰氨基酚)和尼美舒利 3 天疗程,不良事件发生在感染登革热的第五天。停用违禁药物后,患者通过支持性治疗和水合疗法得以存活:结论:合并症的存在不一定是引发 TEN 的因素,但会影响患者的预后。建议在护理病人时合理用药。要了解病毒-药物-基因相互作用背后的病理机制,还需要进一步的研究。
{"title":"A Case Report of Cefixime, Paracetamol, and Nimesulide Induced Toxic Epidermal Necrolysis in a Woman with Dengue Infection without any Other Associated Comorbidities.","authors":"Renuka Munshi, Miteshkumar Maurya","doi":"10.2174/1574886318666230418104445","DOIUrl":"10.2174/1574886318666230418104445","url":null,"abstract":"<p><strong>Background: </strong>Toxic Epidermal Necrolysis (TEN) is a rare, acute, and life-threatening mucocutaneous disease that occurs after the administration of certain drugs, resulting in extensive keratinocyte cell death, skin involvement at the dermal-epidermal junction, and extensive bullous skin eruptions and sloughing. Many published case reports have observed the presence of fever with a viral infection, drug, and/or genetic association as a possible trigger for TEN but associated with other comorbidities. Physicians still struggle to predict which individuals could be predisposed to TEN. The case report that we present had a history of multiple drug intake and fever due to dengue virus infection but was not associated with any other comorbidity.</p><p><strong>Case presentation: </strong>We present an unusual case of a 32-year-old woman of Western Indian origin who had developed dengue infection and suffered toxic epidermal necrolysis following a five-day course of a third-generation cephalosporin antibiotic, cefixime and a three-day course of 2 analgesic drugs, paracetamol (acetaminophen), and nimesulide, with the adverse event occurring on the fifth day of the dengue infection. The offending drugs were stopped, and patient survived with supportive management and hydration.</p><p><strong>Conclusion: </strong>The presence of comorbidities may not always be the triggering factor for TEN, though it can affect patient outcomes. Rational drug use is always recommended for patient care. Further research is required to understand the pathomechanism behind the viral-drug-gene interaction.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":"286-290"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9420436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of Cardiovascular Events with COVID-19 Vaccines Using Vaccine Adverse Event Reporting System (VAERS): A Retrospective Study. 使用疫苗不良事件报告系统(VAERS)的心血管事件与COVID-19疫苗的关联:一项回顾性研究
IF 1.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/0115748863276904231108095255
Mohd Amir, S Latha, Ruchika Sharma, Anoop Kumar

Background: COVID-19 vaccines have played a crucial role in reducing the burden of the global pandemic. However, recent case reports have indicated the association of the COVID- 19 vaccines with cardiovascular events but the exact association is unclear so far.

Objective: Therefore, the objective of the current study is to find out the association of cardiovascular events with COVID-19 vaccines.

Methods: The COVID-19 Vaccine Knowledge Base (Cov19VaxKB) tool was used to query the Vaccine Adverse Event Reporting System (VAERS) database. The proportional reporting ratio [PRR (≥2)] with associated chi-squared value (>4), and the number of cases > 0.2% of total reports, was used to assess the association of COVID-19 vaccines with cardiovascular events.

Results: A total of 33,754 cases of cardiovascular events associated with COVID-19 vaccines were found in the Cov19VaxKB tool. The cases were observed in different age groups (18-64, and 65 years and above) and gender. The disproportionality measures indicate a statistically significant association between cardiovascular events and COVID-19 vaccines.

Conclusion: The current study identified a signal of various cardiovascular events with the COVID-19 vaccines. However, further causality assessment is required to confirm the association.

背景:COVID-19疫苗在减轻全球大流行负担方面发挥了至关重要的作用。然而,最近的病例报告表明COVID- 19疫苗与心血管事件有关,但目前尚不清楚确切的联系。目的:因此,本研究的目的是了解心血管事件与COVID-19疫苗的关系。方法:采用COVID-19疫苗知识库(Cov19VaxKB)工具查询疫苗不良事件报告系统(VAERS)数据库。采用相关卡方值(>4)且病例数>总报告数的比例报告比[PRR(≥2)],评估COVID-19疫苗与心血管事件的相关性。结果:在Cov19VaxKB工具中共发现了33754例与COVID-19疫苗相关的心血管事件。病例分布在不同年龄组(18-64岁,65岁及以上)和性别。歧化测量表明,心血管事件与COVID-19疫苗之间存在统计学上显著的关联。结论:目前的研究确定了COVID-19疫苗可引起各种心血管事件的信号。然而,需要进一步的因果关系评估来证实这种关联。
{"title":"Association of Cardiovascular Events with COVID-19 Vaccines Using Vaccine Adverse Event Reporting System (VAERS): A Retrospective Study.","authors":"Mohd Amir, S Latha, Ruchika Sharma, Anoop Kumar","doi":"10.2174/0115748863276904231108095255","DOIUrl":"10.2174/0115748863276904231108095255","url":null,"abstract":"<p><strong>Background: </strong>COVID-19 vaccines have played a crucial role in reducing the burden of the global pandemic. However, recent case reports have indicated the association of the COVID- 19 vaccines with cardiovascular events but the exact association is unclear so far.</p><p><strong>Objective: </strong>Therefore, the objective of the current study is to find out the association of cardiovascular events with COVID-19 vaccines.</p><p><strong>Methods: </strong>The COVID-19 Vaccine Knowledge Base (Cov19VaxKB) tool was used to query the Vaccine Adverse Event Reporting System (VAERS) database. The proportional reporting ratio [PRR (≥2)] with associated chi-squared value (>4), and the number of cases > 0.2% of total reports, was used to assess the association of COVID-19 vaccines with cardiovascular events.</p><p><strong>Results: </strong>A total of 33,754 cases of cardiovascular events associated with COVID-19 vaccines were found in the Cov19VaxKB tool. The cases were observed in different age groups (18-64, and 65 years and above) and gender. The disproportionality measures indicate a statistically significant association between cardiovascular events and COVID-19 vaccines.</p><p><strong>Conclusion: </strong>The current study identified a signal of various cardiovascular events with the COVID-19 vaccines. However, further causality assessment is required to confirm the association.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":"402-406"},"PeriodicalIF":1.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138458400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Effect of Renal Replacement Therapy in a Patient with Mercaptopurine Toxicity: Time to Revise Guidelines. 肾脏替代疗法对巯嘌呤中毒患者的影响:是时候修订指南了
IF 1.5 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/1574886318666230714105801
H J L Quaedvlieg, F N Polderman, M Borkent, De H J M Jonge, P A Annema, L J J Derijks, M A Sikma, C Bethlehem

Introduction: Mercaptopurine, a thiopurine, is used in various disorders of immune regulation, such as autoimmune hepatitis. Thiopurine metabolism is complex with risk for overdosing, especially when metabolism is impaired by liver dysfunction. Hepatotoxicity may be due to mercaptopurine overdose and is often reversible after prompt cessation of the drug.

Case presentation: Treatment of thiopurine toxicity is mainly supportive and literature on enhanced elimination by renal replacement therapy is ambiguous.

Conclusion: In this case of thiopurine toxicity, a patient with autoimmune hepatitis presents with abdominal pain, nausea, vomiting, and diarrhea. We show in this case report that renal replacement therapy had no effect on total body clearance of mercaptopurine.

简介巯嘌呤是一种硫嘌呤类药物,用于治疗各种免疫调节紊乱,如自身免疫性肝炎。硫嘌呤代谢过程复杂,有用药过量的风险,尤其是当肝功能障碍导致代谢受损时。肝中毒可能是由于巯嘌呤用药过量所致,在及时停药后通常可以逆转:病例介绍:硫嘌呤中毒的治疗主要是支持性治疗,关于通过肾脏替代疗法提高排毒效果的文献不明确:在本例硫嘌呤中毒病例中,一名自身免疫性肝炎患者表现为腹痛、恶心、呕吐和腹泻。本病例报告显示,肾脏替代疗法对巯嘌呤的全身清除率没有影响。
{"title":"The Effect of Renal Replacement Therapy in a Patient with Mercaptopurine Toxicity: Time to Revise Guidelines.","authors":"H J L Quaedvlieg, F N Polderman, M Borkent, De H J M Jonge, P A Annema, L J J Derijks, M A Sikma, C Bethlehem","doi":"10.2174/1574886318666230714105801","DOIUrl":"10.2174/1574886318666230714105801","url":null,"abstract":"<p><strong>Introduction: </strong>Mercaptopurine, a thiopurine, is used in various disorders of immune regulation, such as autoimmune hepatitis. Thiopurine metabolism is complex with risk for overdosing, especially when metabolism is impaired by liver dysfunction. Hepatotoxicity may be due to mercaptopurine overdose and is often reversible after prompt cessation of the drug.</p><p><strong>Case presentation: </strong>Treatment of thiopurine toxicity is mainly supportive and literature on enhanced elimination by renal replacement therapy is ambiguous.</p><p><strong>Conclusion: </strong>In this case of thiopurine toxicity, a patient with autoimmune hepatitis presents with abdominal pain, nausea, vomiting, and diarrhea. We show in this case report that renal replacement therapy had no effect on total body clearance of mercaptopurine.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":"299-302"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9778353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Concise Review on Scientific Approaches to Burns and Scars. 烧伤和疤痕科学方法简明综述》。
IF 1.5 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/1574886318666230509143017
Hitesh Malhotra, Prerna Sharma, Mohammad Amjad Kamal, Peeyush Kaushik, Nidhi Rani

Burns are large open surgical lesions bathed in virulent pus that result in rupturing of the cutaneous membrane, which has serious consequences such as an extensive loss of proteins, and body fluids, increased chances of infections, and sometimes death. These can be classified based on their penetration levels, i.e., first-degree burns penetrating the epidermis, second-degree burns including both epidermis and dermis, third-degree burns to both layers including the hair follicular cells, sweat glands and various core tissues, fourth-degree burns to adipose tissue, fifth stage burns to muscles, and sixth stage burns to bones. Wound healing/wound repair is a very perplexing process in which the tissues of the affected/burnt area repairs themselves to attain their original form and functionality but develop a scar at the wound site. This article mainly focuses on the algorithms to differentiate various degrees of burns, general first aid approaches to burns and scars, the rationale of treatment of burns, basic mechanisms highlighting the healing processes in humans in terms of free from scar formation as well as with scar formation at their elementary levels including cellular as well as biochemical levels, utility, and progression of pre-clinical data to humans and finally approaches for the improvement of scar formation in man.

烧伤是一种大面积的开放性外科病变,会出现剧毒脓液,导致皮肤膜破裂,造成蛋白质和体液大量流失、感染几率增加等严重后果,有时甚至会导致死亡。这些烧伤可根据其穿透程度进行分类,即穿透表皮的一级烧伤、包括表皮和真皮在内的二级烧伤、包括毛囊细胞、汗腺和各种核心组织在内的两层烧伤、脂肪组织的四级烧伤、肌肉的五级烧伤和骨骼的六级烧伤。伤口愈合/伤口修复是一个非常令人困惑的过程,在这个过程中,受影响/烧伤部位的组织会进行自我修复,以达到原来的形态和功能,但在伤口部位会形成疤痕。本文主要侧重于区分不同程度烧伤的算法、烧伤和疤痕的一般急救方法、烧伤治疗的基本原理、从无疤痕形成和有疤痕形成的基本层面(包括细胞和生化层面)突出人类愈合过程的基本机制、实用性以及将临床前数据应用于人类的进展,最后是改善人类疤痕形成的方法。
{"title":"Concise Review on Scientific Approaches to Burns and Scars.","authors":"Hitesh Malhotra, Prerna Sharma, Mohammad Amjad Kamal, Peeyush Kaushik, Nidhi Rani","doi":"10.2174/1574886318666230509143017","DOIUrl":"10.2174/1574886318666230509143017","url":null,"abstract":"<p><p>Burns are large open surgical lesions bathed in virulent pus that result in rupturing of the cutaneous membrane, which has serious consequences such as an extensive loss of proteins, and body fluids, increased chances of infections, and sometimes death. These can be classified based on their penetration levels, i.e., first-degree burns penetrating the epidermis, second-degree burns including both epidermis and dermis, third-degree burns to both layers including the hair follicular cells, sweat glands and various core tissues, fourth-degree burns to adipose tissue, fifth stage burns to muscles, and sixth stage burns to bones. Wound healing/wound repair is a very perplexing process in which the tissues of the affected/burnt area repairs themselves to attain their original form and functionality but develop a scar at the wound site. This article mainly focuses on the algorithms to differentiate various degrees of burns, general first aid approaches to burns and scars, the rationale of treatment of burns, basic mechanisms highlighting the healing processes in humans in terms of free from scar formation as well as with scar formation at their elementary levels including cellular as well as biochemical levels, utility, and progression of pre-clinical data to humans and finally approaches for the improvement of scar formation in man.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":"191-199"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9796493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Osimertinib-induced Keratitis and Secondary Toxic Epidermal Necrotic Drug Eruption- A Case Report and Literature Review. 奥西替尼致角膜炎及继发性中毒性表皮坏死药疹1例报告并文献复习。
IF 1.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/1574886318666230529123200
Yunhua Xu, Yong Li, Jie Luo, Rong Tang

Background: Osimertinib is a third-generation Tyrosine Kinase inhibitor, mainly used in non-small cell lung cancer with EGFR mutation. Its efficacy and safety have been confirmed by clinical practice. Toxic epidermolysis necrotizing disease (TEN) is a severe drug eruption that is rare in clinics and has a high mortality rate. Toxic epidermal necrotic drug rash caused by Osimeritinib is even rarer.

Objective: To investigate the rare side effects of Osimertinib through a case of toxic Epidermal necrosis.

Case presentation: A 63-year-old female patient was diagnosed with lung adenocarcinoma with brain metastases, and genetic testing revealed an EGFR21 exon mutation. The disease progressed 24 days after the administration of gefitinib, then the patient switched to Osimertinib (80 mg QD) and, resulting in keratitis and secondary systemic toxic epidermolysis necrotizing disease (TEN). Finally, the patient died.

Conclusion: Although the clinical use of osimertinib is becoming widespread, the side effects may not be fully understood. Clinicians should pay more attention to the occurrence of the side reaction and deal with it in time.

背景:奥西替尼是第三代酪氨酸激酶抑制剂,主要用于EGFR突变的非小细胞肺癌。临床实践证实了其有效性和安全性。中毒性表皮松解性坏死性疾病(TEN)是临床上罕见且死亡率高的严重药疹。由奥西替尼引起的中毒性表皮坏死性药物皮疹更为罕见。目的:通过一例中毒性表皮坏死病例探讨奥西替尼罕见的副作用。病例介绍:一名63岁女性患者诊断为肺腺癌伴脑转移,基因检测发现EGFR21外显子突变。在给予吉非替尼24天后病情进展,随后患者改用奥西替尼(80mg QD),导致角膜炎和继发性系统性中毒性表皮松解性坏死性疾病(TEN)。最后,病人死了。结论:虽然奥西替尼的临床应用越来越广泛,但其副作用尚不完全清楚。临床医生应重视副反应的发生并及时处理。
{"title":"Osimertinib-induced Keratitis and Secondary Toxic Epidermal Necrotic Drug Eruption- A Case Report and Literature Review.","authors":"Yunhua Xu, Yong Li, Jie Luo, Rong Tang","doi":"10.2174/1574886318666230529123200","DOIUrl":"10.2174/1574886318666230529123200","url":null,"abstract":"<p><strong>Background: </strong>Osimertinib is a third-generation Tyrosine Kinase inhibitor, mainly used in non-small cell lung cancer with EGFR mutation. Its efficacy and safety have been confirmed by clinical practice. Toxic epidermolysis necrotizing disease (TEN) is a severe drug eruption that is rare in clinics and has a high mortality rate. Toxic epidermal necrotic drug rash caused by Osimeritinib is even rarer.</p><p><strong>Objective: </strong>To investigate the rare side effects of Osimertinib through a case of toxic Epidermal necrosis.</p><p><strong>Case presentation: </strong>A 63-year-old female patient was diagnosed with lung adenocarcinoma with brain metastases, and genetic testing revealed an EGFR21 exon mutation. The disease progressed 24 days after the administration of gefitinib, then the patient switched to Osimertinib (80 mg QD) and, resulting in keratitis and secondary systemic toxic epidermolysis necrotizing disease (TEN). Finally, the patient died.</p><p><strong>Conclusion: </strong>Although the clinical use of osimertinib is becoming widespread, the side effects may not be fully understood. Clinicians should pay more attention to the occurrence of the side reaction and deal with it in time.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":"309-312"},"PeriodicalIF":1.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9902839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interactions Between Antimicrobial Peptides and Targets Responsible for their Nephrotoxic Action: Molecular Dynamics Simulations. 抗菌肽与肾毒性作用靶点之间的相互作用:分子动力学模拟。
IF 1.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/1574886318666230905100924
Yury Lisnyak, Artur Martynov, Boris Farber

Objectives: Polymyxin is the last line of defense against resistant forms of microorganisms, but it has significant nephrotoxicity. One of the directions in reducing the nephrotoxicity of polymyxin is to modify the charge of the molecule and accordingly, to change the topicity of the polymyxin derivative to the renal megalin. Such modification can lead to a decrease in the accumulation of polymyxin in the kidneys and reduce its toxicity while maintaining its antimicrobial properties. The study aimed to investigate the structural aspects of polymyxin nephrotoxicity at the atomic level to promote the more purposeful development of the polymyxin's derivatives with the lower nephrotoxic action.

Materials and methods: The molecular dynamics simulations of the complexes of polymyxin B and its derivative NAB7061 (that carries only three positive charges located within the macrocycle) with megalin were performed in program package YASARA structure with explicit water (TIP3P) and ions (0.9 % NaCl) in NPT ensemble using the AMRER03 force field. After 10 ns equilibration, each system was simulated at 298 K and pH 7.4 for a 25 ns production phase. Simulations were run twice for each molecular system.

Results: By molecular dynamics simulations, the possibility was shown for polymyxin to form a stable complex with two neighbor structural domains of megalin in accord with the universal mechanism of binding the cationic ligands by ligand-binding CR repeats of the LDLR-family receptors. It was reported that interactions of megalin with polymyxin were stronger than with its derivative having no positively charged groups outside the macrocycle. The structural prerequisites of these differences were revealed, explaining the less nephrotoxicity of such derivatives compared to polymyxin.

Conclusion: Comparative molecular dynamics simulations of megalin interactions with polymyxin B and its derivative NAB7061, which carries no positive charges outside the macrocycle, revealed the possible structural prerequisites for the lower nephrotoxic action of such polymyxin derivatives. The weakening of polymyxins binding with megalin may become an effective preventive measure against polymyxin-induced nephrotoxicity.

目的:多粘菌素是抵抗耐药性微生物的最后一道防线,但它具有明显的肾毒性。降低多粘菌素肾毒性的方向之一是改变分子的电荷,从而改变多粘菌素衍生物对肾脏巨球蛋白的主题性。这种改变可以减少多粘菌素在肾脏中的蓄积,降低其毒性,同时保持其抗菌特性。该研究旨在从原子水平研究多粘菌素肾毒性的结构方面,以促进更有针对性地开发具有较低肾毒性作用的多粘菌素衍生物:多粘菌素 B 及其衍生物 NAB7061(在大循环中只带三个正电荷)与巨霉素的复合物的分子动力学模拟是在程序包 YASARA 结构中进行的,其中包含显式水(TIP3P)和离子(0.9 % NaCl),并在 NPT 集合中使用 AMRER03 力场。经过 10 ns 的平衡后,每个系统在 298 K 和 pH 7.4 的条件下模拟了 25 ns 的生产阶段。每个分子体系模拟两次:通过分子动力学模拟,多粘菌素有可能与 megalin 的两个相邻结构域形成稳定的复合物,这与 LDLR 家族受体的配体结合 CR 重复序列结合阳离子配体的普遍机制一致。据报道,巨球蛋白与多粘菌素的相互作用强于与其大环外不带正电荷基团的衍生物的相互作用。研究揭示了这些差异的结构前提,从而解释了为什么与多粘菌素相比,这种衍生物的肾毒性较低:结论:通过对巨球蛋白与多粘菌素 B 及其衍生物 NAB7061(其大循环外不带有正电荷)相互作用的分子动力学比较模拟,发现了此类多粘菌素衍生物具有较低肾毒性作用的可能结构前提。减弱多粘菌素与巨球蛋白的结合可能成为预防多粘菌素引起的肾毒性的有效措施。
{"title":"Interactions Between Antimicrobial Peptides and Targets Responsible for their Nephrotoxic Action: Molecular Dynamics Simulations.","authors":"Yury Lisnyak, Artur Martynov, Boris Farber","doi":"10.2174/1574886318666230905100924","DOIUrl":"10.2174/1574886318666230905100924","url":null,"abstract":"<p><strong>Objectives: </strong>Polymyxin is the last line of defense against resistant forms of microorganisms, but it has significant nephrotoxicity. One of the directions in reducing the nephrotoxicity of polymyxin is to modify the charge of the molecule and accordingly, to change the topicity of the polymyxin derivative to the renal megalin. Such modification can lead to a decrease in the accumulation of polymyxin in the kidneys and reduce its toxicity while maintaining its antimicrobial properties. The study aimed to investigate the structural aspects of polymyxin nephrotoxicity at the atomic level to promote the more purposeful development of the polymyxin's derivatives with the lower nephrotoxic action.</p><p><strong>Materials and methods: </strong>The molecular dynamics simulations of the complexes of polymyxin B and its derivative NAB7061 (that carries only three positive charges located within the macrocycle) with megalin were performed in program package YASARA structure with explicit water (TIP3P) and ions (0.9 % NaCl) in NPT ensemble using the AMRER03 force field. After 10 ns equilibration, each system was simulated at 298 K and pH 7.4 for a 25 ns production phase. Simulations were run twice for each molecular system.</p><p><strong>Results: </strong>By molecular dynamics simulations, the possibility was shown for polymyxin to form a stable complex with two neighbor structural domains of megalin in accord with the universal mechanism of binding the cationic ligands by ligand-binding CR repeats of the LDLR-family receptors. It was reported that interactions of megalin with polymyxin were stronger than with its derivative having no positively charged groups outside the macrocycle. The structural prerequisites of these differences were revealed, explaining the less nephrotoxicity of such derivatives compared to polymyxin.</p><p><strong>Conclusion: </strong>Comparative molecular dynamics simulations of megalin interactions with polymyxin B and its derivative NAB7061, which carries no positive charges outside the macrocycle, revealed the possible structural prerequisites for the lower nephrotoxic action of such polymyxin derivatives. The weakening of polymyxins binding with megalin may become an effective preventive measure against polymyxin-induced nephrotoxicity.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":"342-349"},"PeriodicalIF":1.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10153047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Current drug safety
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1